Protego Biopharma, a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, announced the completion of an oversubscribed $130 million Series B financing.

Protego Biopharma是一家临床阶段的生物技术公司，致力于开创首创新型小分子治疗药物，通过重新编程蛋白质折叠来应对系统性淀粉样变病和其他蛋白质错误折叠疾病，该公司宣布已完成超额认购的1.3亿美元B轮融资。

The round was led by Novartis Venture Fund and Forbion, with participation from new investors including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Existing investors, including Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research, also participated, underscoring their continued conviction in the Protego approach..

本轮融资由诺华创投基金和Forbion领投，新投资者包括Omega Funds、Droia Ventures、YK Bioventures和Digitalis Ventures参与。现有投资者如Vida Ventures、MPM BioImpact、Lightspeed Venture Partners和Scripps Research也参与其中，进一步彰显了他们对Protego方法的持续信心。